ClariVein®OC is a specialty infusion catheter for the occlusion of incompetent veins in patients with superficial venous reflux.
ClariVein®OC is designed with a low profile for ease of entry and patient comfort to facilitate fast return to work and normal activities.
What Are Varicose Veins?
Varicose veins are enlarged, bulging veins that appear on the surface of the skin on your legs.
The underlying cause of varicose veins is venous reflux disease, which occurs when the tiny valves inside your leg veins that control blood flow from your legs to your heart become damaged.
In addition to causing unsightly and sometimes painful varicose veins, left untreated, venous reflux disease can progress to create other more serious circulatory and skin problems in your legs.
What Happens If I Leave My Varicose Veins Untreated?
Unfortunately, the disease does not get better without intervention. If varicose veins are left untreated, the disease can be debilitating and may even worsen. The good news, however, is that today there are treatments available, which can effectively resolve your varicose veins with very little pain, allowing you to return to your normal routine quickly.
What Are The Treatment Choices?
All procedures have the same goal: By removing or closing the varicose vein, blood will naturally take an alternative path to non-affected veins in your legs, which take over returning blood from your legs to your heart.
Previously, the most common treatment for varicose veins was a painful surgery called “vein stripping”, which was performed in the operating room, removing the problem veins entirely. This remained the gold standard until the early 2000’s when minimally invasive thermal technology emerged as an alternative standard of care.
Today, your doctor offers MOCA (Mechanical Ablation, Chemically Assisted). Using the ClariVein®OC catheter to treat the underlying cause of incompetent veins in patients with superficial venous reflux. Studies show the ClariVein®OC offers many advantages including a reduction in pain, faster return to work and normal activities.1
What is ClariVein®OC?
ClariVein®OC is a specialty infusion catheter with a rotating wire tip designed for the controlled 360-degree dispersion of physician-specified agents to the targeted treatment area.
The ClariVein®OC device is a slim, thin catheter (tube) that your doctor temporarily inserts into the peripheral vasculature through a pin-sized entrance point. ClariVein®OC is several times smaller than other devices used in peripheral vascular treatments allowing the entrance point to be smaller.
Why Choose ClariVein®OC?
Procedures which use ClariVein®OC are often simpler, faster and studies have shown up to 74% less pain than other minimally-invasive peripheral vascular treatments1. Because no thermal energy is used, there is no need for the multiple needle-stick injections of anesthesia (pain-numbing) medication along the length of the treated area. This shortens the time the procedure takes, reduces pain and discomfort, and also eliminates bruising.
Ask Your Doctor if ClariVein®OC is right for you
Ask your doctor about the difference the ClariVein®OC occlusion catheter can offer when compared to other available treatments.
What Happens During the Procedure?
Once placed inside the peripheral vasculature using a pin-sized entry through the skin, the rotating tip of the ClariVein®OC is set in motion to treat the inside of the vessel delivering medicine specified by your doctor. The medicine is delivered through the unique rotating tip of the catheter allowing for 360-degree coverage of the vessel.
The procedure typically takes very little time and creates minimal discomfort.
What Happens After the Procedure?
Follow your Doctor’s instructions for care after your procedure. In some cases rapid return to normal activities can be expected.
1. R. van Eekeren, et al., Postoperative Pain and Early Quality of Life After Radiofrequency Ablation and Mechanochemical Endovenous Ablation of Incompetent Great Saphenous Veins, Journal of Vascular Surgery, Volume 57, Number 2, February 2013, p. 445-450.